Related by context. All words. (Click for frequent words.) 76 free survival PFS 76 Median PFS 73 progression TTP 72 Median survival 72 Median progression 70 % CI #.#-#.# [003] 70 biochemical recurrence 69 Kaplan Meier analysis 69 P = .# 69 CR nPR 69 chlorambucil 69 VcMP 68 p = #.# [004] 68 mg kg dose 68 FOLFOX 68 comparator arm 68 p = #.# [002] 68 % CI #.#-#.# [007] 68 Free Survival PFS 68 pCR 67 lumbar spine BMD 67 mitoxantrone 67 FOLFOX4 67 locoregional 67 plus dexamethasone 67 LVEF 67 HBeAg seroconversion 67 tumor progression TTP 67 mRCC 67 PSADT 66 evaluable 66 evaluable patients 66 FOLFIRI alone 66 virologic response 66 achieved ACR# 66 carboplatin paclitaxel 66 locoregional recurrence 66 prospectively defined 66 mg QD 66 placebo dexamethasone 66 FOLFIRI 66 dacarbazine 66 prior nephrectomy 65 biochemical relapse 65 #mg BID [001] 65 mcg kg 65 EBRT 65 plus prednisone 65 lopinavir r 65 BEACOPP 65 % Confidence Interval 65 achieved CCyR 65 recurrent GBM 65 CR CRu 65 pegylated interferon alfa 2b 65 5FU 65 CCyR 65 5-FU/LV 65 neurologic progression 65 mcg albinterferon alfa 2b 65 VELCADE melphalan 64 plasma uric acid 64 clodronate 64 Doxil ® 64 lopinavir r arm 64 RECIST criteria 64 low dose cytarabine 64 docetaxel 64 tipranavir r 64 pegylated liposomal doxorubicin 64 octreotide LAR 64 virologic failure 64 cisplatin vinorelbine 64 placebo p = 64 chemoradiotherapy 64 mg BID 64 IFN alfa 64 dose dexamethasone 63 peginterferon alfa 2a 63 fluorouracil 63 8mg/kg 63 Fludara 63 HbA1c levels 63 Peg IFN 63 complete cytogenetic response 63 pg mL 63 MACCE 63 MADRS score 63 statistically significant p = 63 APTIVUS r 63 plus gemcitabine 63 neoadjuvant chemotherapy 63 undetectable viral load 63 tumor recurrence 63 interferon alfa 63 gemcitabine 63 DAS# remission 63 chemoradiation 63 peg IFN 63 LEXIVA r 63 azacitidine 63 QTcF 62 sustained virologic response 62 preoperative chemotherapy 62 mutated KRAS 62 undetectable HBV DNA 62 μmol L 62 postintervention 62 response CCyR 62 stage IIIb IV 62 secondary endpoint 62 CIMZIA TM 62 definite stent thrombosis 62 androgen suppression 62 IFN α 62 neoadjuvant therapy 62 patients evaluable 62 tumor shrinkage 62 #mg QD [002] 62 Flu Cy 62 oblimersen 62 disease progression TTP 62 locoregional disease 62 ipsilateral stroke 62 adalimumab 62 low dose Iluvien 62 decitabine 62 FOLFOX4 alone 62 ACR# response 62 XELOX 62 CRu 62 % CI #.#-#.# [006] 62 Partial Responses 62 topotecan 62 PSA nadir 62 Folfox 62 underwent resection 62 plus methotrexate 62 remission CR 62 recurrent VTE 62 Partial Response 62 univariate analysis 62 REYATAZ r 62 HIV RNA 62 complete cytogenetic 62 ribavirin RBV 62 heavily pretreated 62 p = NS 62 lymphocytosis 62 oxycodone CR 62 imatinib 62 #mg QD [001] 62 plus ribavirin 62 mg/m2 dose 62 relapsed MM 62 primary patency 61 temsirolimus 61 ACTEMRA TM 61 postoperatively 61 methotrexate monotherapy 61 severe neutropenia 61 interquartile range 61 contralateral breast 61 undetectable HCV RNA 61 cytogenetic response 61 metastatic renal cell carcinoma 61 cabazitaxel 61 resected pancreatic cancer 61 febrile neutropenia 61 oral Hycamtin 61 FOLPI 61 Elitek 61 docetaxel chemotherapy 61 SVR# 61 microbiological eradication 61 mitoxantrone plus 61 trastuzumab 61 vandetanib 61 estramustine 61 distant metastasis 61 log# copies mL 61 Hazard Ratio 61 oral diclofenac 61 XIENCE V PROMUS Stent 61 nondiabetic patients 61 rapid virologic response 61 EDSS score 61 PEG IFN 61 HBeAg positive patients 61 NMIBC 61 sunitinib 61 TACE 61 adjunctive placebo 61 4mg/kg 61 mg dose 61 debulking surgery 61 ALND 61 etanercept 61 oral allopurinol 61 postoperative chemotherapy 61 FluCAM 61 Response Evaluation Criteria 61 virological response 61 advanced adenomas 61 mg/m2 61 azathioprine 61 imatinib therapy 61 pT3 61 adjuvant therapy 61 evaluable subjects 61 gemcitabine carboplatin 61 placebo PBO 61 methotrexate therapy 61 PREZISTA ritonavir 61 plus MTX 61 CI #.#-#.# [001] 61 binary restenosis 61 preintervention 61 glufosfamide 61 lymphadenectomy 61 CRp 61 partial remissions 61 mcg QD 61 mcg dose 61 atazanavir ritonavir 61 adjuvant chemotherapy 61 active comparator 61 lamivudine refractory patients 60 mapatumumab 60 gefitinib 60 PREZISTA r 60 radical nephrectomy 60 lamivudine monotherapy 60 #mg/m# [002] 60 dosing cohorts 60 sirolimus eluting stent 60 PASI scores 60 bosentan 60 serum HCV RNA 60 ritonavir boosted 60 goserelin 60 CYPHER Stent 60 CIMZIA ™ 60 p = .# [002] 60 LPV r 60 log# IU mL 60 RGT arm 60 KRAS wild 60 nodular partial response 60 stage IIIB 60 VIDAZA 60 HER2 negative 60 bevacizumab 60 ximelagatran 60 GnRH agonist 60 annualized relapse 60 NATRECOR R 60 paclitaxel eluting stents 60 cancer mCRC 60 #.#ng/ml 60 #mg/m# [001] 60 FOLFOX6 60 primary endpoint 60 mL/min/#.# m 2 60 RECIST Response Evaluation Criteria 60 advanced adenoma 60 confidence interval CI 60 tiotropium 60 pT2 60 noninferiority 60 hepatic metastases 60 F FDG PET 60 mg TID 60 neoadjuvant 60 baseline HbA1c 60 peginterferon alfa 2b 60 R0 resection 60 pemetrexed 60 TMC# r 60 posaconazole 60 #mg BID [003] 60 monotherapy 60 serum phosphorus 60 p = 60 placebo 60 IU ml 60 R# #mg BID 60 cisplatin chemotherapy 60 underwent surgical resection 60 Zometa hazard 60 HBeAg positive 60 HER2 positive metastatic breast 60 adjuvant tamoxifen 60 g dL 60 carboplatin 60 gemcitabine cisplatin 60 mycophenolate mofetil 60 % CI #.#-#.# [002] 59 Solid Tumors RECIST 59 pg ml 59 rimonabant #mg 59 mg m² 59 androgen deprivation 59 DOXIL 59 DAPT 59 timepoints 59 cEVR 59 achieved statistical significance 59 QTc 59 recurrent NSCLC 59 desvenlafaxine succinate 59 certolizumab 59 mcg BID 59 chemoradiation therapy 59 median survivals 59 detectable HCV RNA 59 EDSS scores 59 doxorubicin docetaxel 59 HBeAg 59 sd = 59 abacavir lamivudine 59 mg Lucentis 59 -#.# log# 59 sustained virological response 59 statistically significant improvement 59 MabCampath 59 adefovir 59 thromboembolic events 59 non squamous histology 59 placebo p 59 Neoadjuvant 59 CHOP chemotherapy 59 ng dL 59 dapagliflozin plus 59 YERVOY 59 thymoma 59 #mg dose [002] 59 alfa 2a 59 Thal Dex 59 CPOP R 59 MGd 59 paclitaxel carboplatin 59 Operative mortality 59 tumor histology 59 STELARA 59 #mg/kg [002] 59 diameter stenosis 59 infusional 5-FU/LV 59 idraparinux 59 gemcitabine chemotherapy 59 HBeAg negative 59 mg kg 59 receiving VICTRELIS 59 response pCR 59 melphalan prednisone 59 prior chemotherapy regimens 59 KRAS mutant tumors 59 peginterferon 59 achieved PASI 59 #Gy 59 adjuvant cisplatin 59 CALGB # [002] 59 mg ustekinumab 59 nonmetastatic 59 mIU L 59 liver histology 59 sorafenib Nexavar 59 metastatic RCC 59 invasive carcinomas 59 statistical significance p 59 squamous histology 59 distant metastases 59 HBeAg negative patients 59 HCV RNA 59 Hazard Ratio HR 59 teriflunomide 59 dexamethasone 59 tamsulosin 59 zoledronic acid 59 TORISEL 59 ErbB2 positive 59 disease progression 59 standard chemotherapy regimen 59 apremilast 59 mg/m2 IV 59 mg d 59 postop 59 cytogenetic abnormalities 59 radiotherapy RT 59 dacarbazine DTIC 59 sUA 59 liposomal doxorubicin 58 Psoriasis Area 58 ARCOXIA 58 epirubicin cyclophosphamide 58 HCV RESPOND 2 58 tirofiban 58 unresectable 58 pegylated interferon 58 fluoropyrimidine 58 clinically meaningful improvement 58 iniparib 58 mCRC patients 58 perioperative complications 58 fulvestrant 58 Kaplan Meier estimate 58 virologic 58 histologically confirmed 58 baseline LDH 58 KRAS mutations occur 58 capecitabine 58 care regimens CCR 58 Aptivus ® 58 leukemia AML 58 log# reduction 58 HCV genotype 58 efficacy endpoint 58 Taxotere ® 58 leukopenia 58 oral clodronate 58 angiographic restenosis 58 TAXUS Express Stent 58 receiving golimumab 58 amoxicillin clavulanate 58 PCa 58 hip BMD 58 mg Proellex 58 endoscopic remission 58 colorectal metastases 58 REYATAZ r arm 58 daunorubicin 58 Torisel 58 idarubicin 58 bortezomib 58 CIMZIA TM certolizumab pegol 58 n = 58 mL/min/#.# m2 58 EURIDIS 58 lung metastases 58 posttransplant 58 g dl 58 6MWD 58 DAS# [002] 58 locoregional control 58 remission induction 58 mcg Albuferon 58 #mg BID [002] 58 RECIST 58 NEVO ™ 58 dose cohort 58 neostigmine 58 nab paclitaxel 58 breast carcinoma 58 recurrent glioblastoma multiforme 58 melphalan 58 % CI #.#-#.# [005] 58 Engerix B 58 colorectal carcinoma 58 reinfarction 58 octreotide 58 serum prostate 58 piperacillin tazobactam 58 plus OBT 58 operable breast cancer 58 preoperative PSA 58 infliximab monotherapy 58 pancreatic adenocarcinoma 58 relapsed AML 58 ribavirin therapy 58 pegylated interferon alfa 2a 58 log# 58 mg/m2/day 58 hours postdose 58 adjuvant radiotherapy 58 telaprevir dosed 58 SUVmax 58 Bezielle 58 ABC/3TC 58 composite endpoint 58 HbA 1c 58 corticosteroid dose 58 ACZ# 58 QRS duration 58 antibody titer 58 docetaxel pretreated 58 dasatinib 58 % CI #.#-#.# [008] 58 nonfatal MI 58 IELT 58 contralateral breast cancer 58 nadolol 58 aminotransferase elevations greater 58 microbiologically evaluable 58 systemic embolism 58 dose cohorts 58 pomalidomide 58 ACR# responses 58 BARACLUDE ® 58 BRIM2 58 HER2 expression 58 hematologic toxicity 58 CTEPH 58 FROVA 58 tapentadol ER 58 tamoxifen therapy 58 Ishak fibrosis score 58 Scale EDSS 58 Kaplan Meier 58 localized renal 58 seroprotection 58 timepoint 58 copies ml 58 adriamycin 58 bortezomib refractory 58 low dose dexamethasone 58 platinum refractory 58 letrozole 58 ABVD 58 tocilizumab 58 nephrectomy 58 clinically localized prostate 58 thyroglobulin 58 IPSS 58 gout flares 58 darunavir ritonavir 58 copies mL 58 HbA1c 58 temozolomide 58 tipranavir ritonavir 58 BRCA2 mutation carriers 58 CIN3 58 ULORIC 58 PegIFN RBV 58 doxorubicin cyclophosphamide 58 Amrubicin 58 Hazard Ratio = 58 cytoreduction 58 CC genotype 58 adalimumab Humira 58 Kaplan Meier estimates 58 morphometric vertebral fractures 58 mesalamine granules 58 mg p = 58 rFSH 58 CLARITY study 58 specific antigen PSA 58 Pegasys plus Copegus 57 iodixanol 57 experienced virologic failure 57 anemia hemoglobin 57 renal insufficiency 57 cetuximab 57 ≥ 57 TroVax ® 57 #.#mg/dL 57 splenectomized patients 57 adjuvant radiation 57 seroconversion 57 postoperative mortality 57 Taxus Stent 57 MCyR 57 SCr 57 trabectedin 57 postmenopausal osteoporotic women 57 Solid Tumors criteria 57 IU mL 57 elevated ALT 57 iniparib BSI 57 Teriflunomide 57 seliciclib 57 oral rivaroxaban 57 evaluating tivozanib 57 cilostazol 57 #.#/#.# mmHg [001] 57 EGFR TKI 57 MMSE scores 57 urate lowering therapy 57 confirmed CCyR 57 metastatic castration resistant 57 ritonavir boosted atazanavir 57 HDRS 57 tumor xenograft models 57 5-fluorouracil/leucovorin 57 neoadjuvant treatment 57 interferon alfa 2a 57 liver metastases 57 CI #.#-#.# [002] 57 Expanded Disability Status 57 reach statistical significance 57 CANCIDAS 57 discontinuations due 57 anthracycline taxane 57 dose cytarabine 57 GOUT 57 alanine aminotransferase ALT 57 intravesical therapy 57 antiretroviral naïve 57 SLNB 57 solifenacin 57 retinal thickness 57 pmol L 57 sirolimus eluting stents 57 atheroma volume 57 lumbar spine bone 57 PREZISTA rtv 57 infliximab 57 metastatic malignant melanoma 57 heavily pretreated patients 57 cystectomy 57 ug kg 57 Tavocept 57 abatacept 57 mg qd 57 T2 lesions 57 Irinotecan 57 metastatic GIST 57 dexamethasone Decadron 57 μg ml 57 p = #.# [003] 57 univariate 57 DES implantation 57 radiographic progression 57 total thyroidectomy 57 creatinine clearance 57 plasma HCV RNA 57 #mg dosing group 57 nilotinib 57 ug dose 57 leukocyte count 57 anastrozole 57 satraplatin Phase 57 serum concentrations 57 angiographic outcomes 57 APTIVUS 57 LAB GHRH 57 Lenalidomide 57 MELD scores 57 concurrent chemoradiation 57 TURBT 57 events MACE 57 TTF Therapy 57 confidence interval #.#-#.# 57 #mg/day [001] 57 serum urate 57 hepatocellular carcinomas 57 sorafenib 57 bendamustine 57 mg m 57 RG# [001] 57 Viread Emtriva Sustiva 57 oral antidiabetic medication 57 comparator PI r 57 TEAEs 57 TLUS 57 lymph node metastasis 57 lowest tertile 57 Secondary endpoints included 57 sunitinib malate 57 hsCRP levels 57 logMAR 57 relapsing multiple sclerosis 57 IV bisphosphonates 57 flutamide 57 target vessel revascularization 57 pneumonectomy 57 serum testosterone 57 axitinib 57 metastatic CRC 57 virological failure 57 crizotinib PF # 57 estrogen receptor progesterone receptor 57 ovarian carcinoma 57 fosamprenavir 57 imetelstat 57 HbA 1c levels 57 RRMS patients 57 TAXUS p value 57 erlotinib 57 virologic responses 57 gemcitabine Gemzar 57 inflammatory lesions 57 LV dysfunction 57 microg 57 primary efficacy endpoint 57 NLX P# 57 posttreatment 57 nonresponders 57 IV NSCLC 57 radical prostatectomy RP 57 DAS# CRP 57 postoperative complication 57 sirolimus stent 57 icatibant 57 diagnosed multiple myeloma 57 paclitaxel chemotherapy 57 alemtuzumab treated 57 Rate ORR 57 radiochemotherapy 57 Ceplene/IL-2 57 Target Lesion Revascularization TLR 57 mmol l 57 rapid virological response 57 genotype 1b 57 Hb A1C 56 somatostatin analog 56 AGILECT R 56 multivariable analysis 56 entecavir 56 cGy 56 darunavir r 56 tolterodine ER 56 % CI #.#-#.# [001] 56 rindopepimut 56 multivariate Cox 56 stent binary restenosis 56 gastrointestinal stromal tumor GIST 56 sleeve lobectomy 56 CLL SLL 56 nonmetastatic prostate cancer 56 adenoma recurrence 56 dacarbazine chemotherapy 56 mCi kg 56 x ULN 56 basal cell carcinoma BCC 56 events AEs 56 sorafenib Nexavar ® 56 hypercalcemia 56 doxorubicin HCl liposome injection 56 biliary tract cancer 56 nmol liter 56 vicriviroc 56 sham injections 56 Pred Forte 56 preoperatively 56 vertebral fracture 56 atypical hyperplasia 56 TAXUS Liberte Long 56 glargine 56 adenoma 56 XGEVA 56 STRIDE PD 56 mIU mL 56 colorectal liver metastases 56 antibody titers 56 administered subcutaneously 56 KRAS mutations 56 antiretroviral naive 56 recurrent GBM patients 56 metastatic HRPC 56 FOLPI regimen 56 mg administered orally 56 levofloxacin 56 HCV genotype 1 56 PREZISTA r arm 56 nmol L 56 dalteparin 56 genotypic resistance 56 eribulin 56 TAXUS Stent 56 EGFR mutation positive 56 secondary efficacy endpoints 56 intestinal metaplasia 56 ATACAND 56 alanine aminotransferase 56 intima media thickness 56 highly emetogenic 56 titrated glipizide 56 afatinib 56 secondary efficacy endpoint 56 resectable 56 splenectomized 56 RLAI 56 doxazosin 56 neovascular glaucoma 56 DMARD 56 untreated multiple myeloma 56 baminercept 56 undetectable virus HCV 56 cyclophosphamide 56 CIN2 + 56 EFAPROXYN 56 ZACTIMA 56 K ras mutations 56 COPEGUS 56 Left Ventricular Ejection Fraction 56 PCWP 56 pegylated interferon alfa 56 symptomatic intracerebral hemorrhage 56 BCVA 56 seminal vesicle invasion 56 GLIADEL R Wafer 56 TIMP 56 pegylated interferon alpha 56 irinotecan cisplatin 56 TIMP 1 56 complete remissions 56 μg L 56 PANSS scores 56 intermittent dosing 56 doripenem 56 3mg/kg 56 abiraterone acetate 56 previously untreated follicular 56 serum phosphate levels 56 small lymphocytic lymphoma 56 reintervention 56 refractory NSCLC 56 moderately emetogenic 56 trabedersen 56 null responders 56 fluorouracil leucovorin 56 IV bolus 56 nodal metastases 56 dosage regimens 56 FluCAM arm 56 TOP2A 56 statistically significant p 56 metformin monotherapy 56 Cmax 56 serum phosphate 56 non squamous NSCLC 56 metastatic renal cell 56 ischemic cardiomyopathy 56 plus prednisone prednisolone 56 clinicopathological features 56 achieved sustained virological 56 CMV disease 56 cTnI 56 creatinine ratio 56 A1c levels 56 relapsed ovarian cancer 56 μg kg 56 cisplatin 56 Adjuvant chemotherapy 56 Secondary endpoints 56 tPSA 56 completely resected 56 fallopian tube carcinoma 56 taxane chemotherapy 56 PEG interferon 56 HAQ DI 56 APPRAISE 56 Pharmacokinetics PK 56 AVODART 56 HER2 positive tumors 56 intravenous cyclophosphamide 56 docetaxel Taxotere 56 lispro 56 β blockers 56 hemoglobin A1c levels 56 lymphopenia 56 tobramycin inhalation solution 56 saline placebo 56 demonstrated statistically significant 56 CYPHER ® Stent 56 mCi 56 serum HBV DNA 56 ertapenem 56 CsA 56 ACR# [002] 56 colorectal carcinomas 56 Tumor shrinkage 56 bone metastasis 56 tolvaptan 56 XIENCE V demonstrated 56 mU liter 56 AUC0 56 Baseline characteristics 56 cytogenetic responses 56 FDG uptake 56 castrate resistant 56 #mg ATC 56 UPDRS scores 56 Q2W 56 mg dL 56 efavirenz EFV 56 prucalopride 56 noninferior 56 peg interferon 56 pamidronate 56 viral kinetics 56 quetiapine 56 bicalutamide 56 salmeterol fluticasone 56 demonstrated antitumor activity 56 HOMA IR 56 irinotecan chemotherapy 56 moderate renal impairment 56 galiximab 56 NATRECOR ® 56 mIU ml 56 FLT3 ITD 56 nucleoside naive 56 virologic suppression 56 papillary thyroid carcinoma 56 CI -#.# 56 #mg q8h 56 degarelix 56 lymph node dissection 56 docetaxel prednisone 56 endocrine therapies 56 epirubicin 56 ng mL 56 HIV uninfected 56 OAB symptoms 56 laboratory abnormalities 56 QTc prolongation 56 endocrine therapy 56 Capecitabine 56 platelet reactivity 56 allogeneic SCT 56 lymph node metastases 56 efficacy evaluable 56 clinically meaningful improvements 56 placebo controlled clinical 56 vinorelbine 56 etoposide 56 lymph node involvement 56 eGFR 56 DTIC 56 nitazoxanide 55 radical cystectomy 55 lenalidomide dexamethasone 55 bosutinib 55 subtrochanteric 55 mean baseline A1C 55 mg kg cohorts 55 DMARDs 55 dose regimens 55 diagnosed GBM 55 TYKERB 55 chemo radiotherapy 55 randomized blinded 55 plus medroxyprogesterone acetate 55 Pemetrexed 55 estrogen receptor ER 55 bupivacaine 55 Stent thrombosis 55 irbesartan 55 -#.# log# copies mL 55 5 FU 55 insulin detemir 55 Sandostatin LAR 55 PEGINTRON TM 55 HbA1C 55 HbA1C levels 55 sinus rhythm 55 BR.# 55 metastatic gastric 55 epithelial ovarian cancer 55 interferon beta 1a 55 Navelbine 55 PNH patients 55 NOXAFIL 55 Hycamtin ® 55 pharmacokinetics PK 55 adjuvant colon cancer 55 Halaven 55 metastatic hormone refractory 55 antithymocyte globulin 55 dose melphalan 55 telbivudine 55 anthracyclines taxanes 55 subcutaneous enoxaparin 55 prednisone prednisolone 55 nonoperative 55 KRAS status 55 non splenectomized 55 TPV r 55 neoadjuvant radiation 55 NPH insulin 55 mammographic density 55 differentiated thyroid 55 DAS# scores 55 PD LID 55 ZOMIG Nasal Spray 55 Gemcitabine 55 Virologic 55 Pegylated Liposomal Doxorubicin 55 CrCl 55 vincristine doxorubicin 55 neutrophil counts 55 mucosal healing 55 ibandronate 55 interferon alfa 2b 55 corrected QT interval 55 unfractionated heparin 55 adjunctive ABILIFY 55 MAGE A3 ASCI 55 untreated metastatic colorectal 55 seroconverted 55 humanized interleukin 6 55 postoperative radiotherapy 55 intraocular inflammation 55 virologic breakthrough 55 hepatic insulin sensitivity 55 HCV SPRINT 55 REMICADE monotherapy 55 NNRTI resistance